Related Experiment Video

Updated: Aug 7, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Nosocomial pneumonia

Uwe Ostendorf1, Santiago Ewig, Antoni Torres

  • 1Thoraxzentrum Ruhrgebiet, Evangelisches Krankenhaus Herne und Augusta-Kranken-Anstalt Bochum, Bochum, Germany.

Current Opinion in Infectious Diseases
|June 29, 2006
PubMed
Abstract

Insights

Recent advances in nosocomial pneumonia management include updated guidelines and improved diagnostic methods for ventilator-associated pneumonia. Beta-lactam monotherapy is preferred over combination therapy to prevent resistance and reduce toxicity.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Pulmonology

Background:

  • Nosocomial pneumonia, including ventilator-associated pneumonia (VAP), presents a growing challenge due to increasing multidrug-resistant (MDR) bacteria.
  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant concern in nosocomial infections.

Purpose of the Study:

  • To review recent advances in the management and prevention of nosocomial pneumonia.
  • To highlight the impact of new American Thoracic Society (ATS) guidelines on clinical practice, particularly outside the USA.

Main Methods:

  • Review of current literature on nosocomial pneumonia management and prevention.
  • Analysis of new ATS guidelines and their implications.
  • Evaluation of diagnostic strategies for VAP.
  • Assessment of antimicrobial therapy efficacy and resistance patterns.

Main Results:

  • The incidence of nosocomial pneumonia caused by MDR bacteria, especially MRSA, is rising.
  • Serial tracheobronchial aspirates can aid in selecting appropriate antimicrobial treatment for VAP, despite diagnostic challenges.
  • Beta-lactam monotherapy demonstrates superior clinical outcomes and better resistance prevention compared to combined beta-lactam and aminoglycoside therapy, with lower nephrotoxicity risk.

Conclusions:

  • Updated ATS guidelines will significantly influence the clinical approach to nosocomial and healthcare-associated pneumonia.
  • Serial tracheobronchial aspirates are valuable for guiding antimicrobial selection in VAP.
  • Combined beta-lactam and aminoglycoside therapy is likely to be phased out.
  • There is an urgent need for novel therapeutic options for pneumonia caused by nonfermenting bacteria.

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: